Dachaigh › Galar Depressive Mòr › Ohio
Sgrùdaidhean clionaigeach Galar Depressive Mòr ann an Ohio
Tha 29 sgrùdaidhean airson Galar Depressive Mòr a’ lorg phàirtichean aig làraichean ann an Ohio.
Bailtean ann an Ohio
- Cincinnati11 sgrùdadh
- Cleveland8 sgrùdaidhean
- Columbus8 sgrùdaidhean
- Parma5 sgrùdaidhean
- Akron4 sgrùdaidhean
Teacsa sgrùdaidh oifigeil (Beurla)
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Neuro-Behavioral Clinical Research, North Canton
A’ fastadhÌre 2
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07284667A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Cleveland Clinic, Cleveland
A’ fastadhÌre 3
Aoisean 18 gu 74 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07592689A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Patient Priority Clinical Sites LLC, Cincinnati
A’ fastadhÌre 3
Aoisean 18 gu 74 · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT07573176Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Quest Therapeutics of Avon Lake, Avon Lake
- University of Cincinnati Medical Center, Cincinnati
- The Ohio State University, Columbus
A’ fastadhÌre 3
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Cincinnati, Cincinnati
A’ fastadhÌre 3
Aoisean 12 gu 17 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07227454Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Patient Priority Clinical Sites LLC, Cincinnati
- The Ohio State University, Columbus
A’ fastadhÌre 3
Aoisean 18 gu 74 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06559306Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Cincinnati
A’ fastadhÌre 3
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Independence
A’ fastadhÌre 4
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Sult 2026 · NCT07105111A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Independence
- Seaport Investigator Site, North Canton
A’ fastadhÌre 2
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT07065240A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Insight Clinical Trials, Independence
A’ fastadhÌre 3
Aoisean 18 gu 74 · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Columbus
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
A’ fastadh
Aoisean 22 gu 70 · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT06423430Positive Processes and Transition to Health (PATH)
- Case Western Reserve University, Cleveland
A’ fastadh
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT06093906NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Mason
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Lùna 2026 · NCT06911112Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
A’ fastadhÌre 2
Aoisean 18 gu 64 · Gach gnè · Air ùrachadh 3 Lùna 2026 · NCT06547489A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Neuro-Behavioral Clinical Research, North Canton
A’ fastadhÌre 3
Aoisean 18 gu 74 · Gach gnè · Air ùrachadh 3 Lùna 2026 · NCT06775379Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
- Lindner Center of Hope, Mason
A’ fastadhÌre 1/2
Aoisean 18 gu 60 · Gach gnè · Air ùrachadh 3 Lùna 2026 · NCT06795451A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
A’ fastadhÌre 2
Aoisean 18 gu 64 · Gach gnè · Air ùrachadh 27 Iuch 2026 · NCT07115329Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Cincinnati
- Clinical Research Site, Cincinnati
A’ fastadhÌre 3
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 24 Iuch 2026 · NCT07484217Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Iuch 2026 · NCT06966401A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
- The Ohio State University Department of Psychiatry, Columbus
A’ fastadhÌre 2
Aoisean 21 gu 65 · Gach gnè · Air ùrachadh 23 Iuch 2026 · NCT06820723A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Quest Therapeutics of Avon /ID# 277550, Avon Lake
- OSU Psychiatry Department /ID# 277529, Columbus
A’ fastadhÌre 2
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 15 Ògmh 2026 · NCT07276997A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- The Ohio State University, Columbus
- Neuro Behavioral Clinical Research, Inc., North Canton
A’ fastadhÌre 2
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 11 Cèit 2026 · NCT06524830Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
- Cincinnati Childrens Hospital Medical Center, Cincinnati
A’ fastadh
Aoisean 14 gu 18 · Gach gnè · Air ùrachadh 11 Gearr 2026 · NCT07217444Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #109, Beachwood
A’ fastadhÌre 2
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 20 Faoi 2026 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Dàmh 2025 · NCT06786624Mechanisms of Rumination Change in Adolescent Depression
- Nationwide Children's Hospital, Columbus
- The Ohio State University, Columbus
A’ fastadh
Aoisean 14 gu 17 · Gach gnè · Air ùrachadh 11 Lùna 2025 · NCT03859297Study of ALTO-300 in MDD
- Site 202, Cincinnati
A’ fastadhÌre 2
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 24 Iuch 2025 · NCT05922878A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Cincinnati
A’ fastadhÌre 4
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 23 Faoi 2025 · NCT06223880Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.